☆ 4.5 Article

Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2+breast cancer

BREAST CANCER RESEARCH AND TREATMENT (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

Michael A. Vogelbaum et al.

Summary: The purpose of this study is to provide guidelines for clinicians on treating patients with brain metastases from solid tumors. The study conducted a systematic review of the literature and found that surgery is a reasonable option for patients with brain metastases. Local therapy should be given to patients with symptomatic brain metastases, regardless of the systemic therapy used. For patients with asymptomatic brain metastases, local therapy should not be deferred unless specifically recommended. Several regimens were recommended for different types of cancer. For patients with no systemic therapy options, stereotactic radiosurgery (SRS) alone should be offered. Memantine and hippocampal avoidance should be considered for patients receiving whole brain radiation therapy. Patients with low Karnofsky Performance Status and no systemic therapy options do not benefit from radiation therapy.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update Q and A

Naren Ramakrishna et al.

JCO ONCOLOGY PRACTICE (2022)

添加到收藏夹

Review Oncology

Treatment strategies for breast cancer brain metastases

Caroline Bailleux et al.

Summary: Brain metastases from breast cancer are becoming more common and represent a major therapeutic challenge. Surgery and stereotaxic radiosurgery are effective for controlling BCBM.

BRITISH JOURNAL OF CANCER (2021)

添加到收藏夹

Review Oncology

Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review

Michelle D. Hackshaw et al.

Summary: Patients with HER2+ breast cancer who develop brain metastasis typically have poor prognosis. Factors such as younger age, hormone receptor status, tumor size and treatment regimens can affect time to brain metastasis diagnosis and survival after diagnosis. Combination therapies including trastuzumab and lapatinib or trastuzumab and pertuzumab show promise in improving survival in these patients. More research is needed to understand risk factors for brain metastasis and improve treatment options.

BMC CANCER (2021)

添加到收藏夹

Article Oncology

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

Nancy U. Lin et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Systemic Therapy of Central Nervous System Metastases of Breast Cancer

Jose Pablo Leone et al.

CURRENT ONCOLOGY REPORTS (2019)

添加到收藏夹

Article Oncology

LBA19Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: An update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC)

M Untch et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort

Amelie Darlix et al.

BRITISH JOURNAL OF CANCER (2019)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

G. von Minckwitz et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Oncology

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update

Naren Ramakrishna et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

Antonio C. Wolff et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis

Qian Zhang et al.

BREAST CANCER (2016)

添加到收藏夹

Article Oncology

Brain metastases as site of first and isolated recurrence of breast cancer: the role of systemic therapy after local treatment

Anna Niwinska

CLINICAL & EXPERIMENTAL METASTASIS (2016)

添加到收藏夹

Review Oncology

Brain metastasis in breast cancer: a comprehensive literature review

Rezvan Rostami et al.

JOURNAL OF NEURO-ONCOLOGY (2016)

添加到收藏夹

Review Oncology

Response assessment criteria for brain metastases: proposal from the RANO group

Nancy U. Lin et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Article Medicine, General & Internal

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

Sandra M. Swain et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Oncology

The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer

Paul W. Sperduto et al.

JOURNAL OF NEURO-ONCOLOGY (2013)

添加到收藏夹

Article Oncology

Breast cancer subtypes and outcomes of central nervous system metastases

Ulku Y. Arslan et al.

BREAST (2011)

添加到收藏夹

Article Oncology

Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier

Hans-Joachim Stemmler et al.

ANTI-CANCER DRUGS (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.